The pharmaceutical grade p-toluenesulfonic acid market is projected to grow from USD 129.8 million in 2025 to USD 213.5 million by 2035, at a CAGR of 5.1%. Purity≥99% will dominate with a 74.0% market share, while doxycycline will lead the application segment with a 45.0% share.